ClinicalTrials.gg
RecruitingNCT05053997Updated Dec 29, 2025

Navigate - Improving Survival and Quality of Life in Vulnerable Lung Cancer Patients

An interventional study of NAVIGATE in Lung Cancer, sponsored by Zealand University Hospital. Recruiting at 6 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-29.

Sponsored by Zealand University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 124 studies in Lung Neoplasms with a site in Denmark — 35 open to participants now, 47 under way, 8 of them phase 3. Lung Neoplasms · Denmark.

Planned enrollment
36th of 94
250 · median 158
Started
2022
with 5 others
No phase
46 of 124
14 open now
Primary completion
2026-12
later than 17 of 46 live
Registered
83rd of 124
by date
Lead sponsor
4 of 124
Zealand University Hospital

Among the 124 studies in Lung Neoplasms with a site in Denmark, this one is the 36th largest by planned enrollment of the 94 interventional ones that give a count, is one of 6 that started in 2022, is one of 46 with no phase, reaches primary completion later than 17 of the 46 other live ones, and was the 83rd registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

35 of the 124 studies in Lung Neoplasms with a site in Denmark are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 124 studies in Lung Neoplasms with a site in Denmark, or all of them as a file.
02

Study summary

Half of patients with lung cancer face a limited life span of one-year survival, which is characterized by severe physical and psychological symptoms. Differences in stage, comorbidity but also treatment may explain a large proportion of the social inequality in lung cancer survival. Some vulnerable patients may not receive first line treatment as planned either due to poor performance status or if they are not able to adhere to treatment appointments. Knowing how to navigate the health system may be a barrier preventing vulnerable patients in receiving optimal treatment. The primary aim of this randomised, controlled trial is to test whether a nurse-led individually tailored program including systematic screening of symptoms using PROs and a physical training program will significantly improve a composite outcome of survival and quality of life as the primary outcome among vulnerable lung cancer patients compared with standard care. Secondary outcomes include adherence to cancer treatment, symptom burden and overall survival.

Read the detailed description

During a period of 3 years and 10 months, consecutive newly diagnosed (\< 1 week) lung cancer patients will be pre-screened for eligibility and invited to participate at departments of oncology or respiratory medicine in Denmark. Participants (N=250) will be randomized (1:1) to standard treatment plus the intervention (intervention group) or standard treatment (control group) and followed for 1 year. Patients randomized to the control group will receive standard treatment and care consisting of a nurse and a physician, who sees the patient at treatment schedules and during follow-up, i.e. every 3 months for the first 2 years and subsequently annually up to 5 years.

Data will be collected from the intervention and the control group at baseline within 6 weeks after diagnosis, and 3, 6 months and 12 months after diagnosis. Physical tests will be performed at baseline and after 3 and 6 months. Baseline physical tests will be allowed after randomization if patients have difficulties in attending the physiotherapy department within 6 weeks after their diagnosis. Considering that participating patients are vulnerable with limited resources we will proactively support patients in responding to questionnaires electronically, on paper or via telephone as per patient's preference allowing evaluation of the primary and secondary outcomes as well as covariates and mechanisms. The treatment factors will be obtained from the lung cancer clinical database and individual medical journals. In order to develop cost utility analyses, information on use of health services will be retrieved from the national registers.

03

Conditions studied

  • Lung Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years of age
  • Diagnosed with NSCLC at all stages regardless of treatment intension at the participating departments
  • Performance status ≤ 2
  • Vulnerable according to pre-defined criteria

Exclusion criteria

Exclusion Criteria:

  • Severe untreated psychiatric disorder (e.g. psychosis) or cognitive problems (e.g. dementia) preventing
  • Not able to receive treatment
  • Not able to read and understand Danish -
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    NAVIGATE intervention arm

    Nurse navigation

    Behavioral: NAVIGATE

  • No intervention
    Navigate control arm

    Standard treatment and care

Interventions

  • BehavioralNAVIGATE

    Patients' symptoms are systematically monitored by use of bi-weekly patient reported outcomes and nurse navigators will initiate appropriate actions in terms of medical treatment or guidance of self-management strategies. Nurse navigators will motivate and support patients in health behavior changes and in selfmanaging their treatment and symptoms, and, if relevant, refer to existing rehabilitation services at the hospital or at the local rehabilitation center. Physiotherapists will supervise a training program aimed at improving patients' physical function and thus potentially surgery and overall treatment adherence and outcomes.

06

What researchers measure

Primary outcomes

  1. A hierarchical composite outcome of survival and global quality of life

    Measured from death from all causes and the Global Health Status (a subscale of EORTC QLQ-C30)

    Time frame: 3 months from randomization

Secondary outcomes

  1. Overall survival

    Measured by death from all causes

    Time frame: 3 months from randomization

  2. Overall survival

    Measured by death from all causes

    Time frame: 6 months from randomization

  3. Overall survival

    Measured from death from all causes

    Time frame: 12 months from randomization

  4. Adherence to cancer treatment

    Measured by date of skipped treatments or delays if any, and dose administered

    Time frame: 3 months from randomization

  5. Adherence to cancer treatment

    Measured by date of skipped treatments or delays if any, and dose administered

    Time frame: 6 months from randomization

  6. Adherence to cancer treatment

    Measured by date of skipped treatments or delays if any, and dose administered

    Time frame: 12 months from randomization

  7. Symptom burden and health related quality of life

    Measured by EORTC Questionnaire Core 30 (QLQ-C30) and the lung module (QLQ-LC13). The QLQ-C30 questionnaire consists of 30 questions with five functional scales (physical, role, cognitive, emotional and social), three symptom scales, a global health status / QoL scale, and six single items. The QLQ-LC13 module comprises both multi-item and single-item measures of lung cancer-associated symptoms (coughing, haemoptysis, dyspnoea and pain) and side-effects from conventional chemo- and radiotherapy (hair loss,neuropathy, sore mouth and dysphagia). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.

    Time frame: 3 months from randomization

  8. Symptom burden and health related quality of life

    Measured by EORTC Questionnaire Core 30 (QLQ-C30) and the lung module (QLQ-LC13). The QLQ-C30 questionnaire consists of 30 questions with five functional scales (physical, role, cognitive, emotional and social), three symptom scales, a global health status / QoL scale, and six single items. The QLQ-LC13 module comprises both multi-item and single-item measures of lung cancer-associated symptoms (coughing, haemoptysis, dyspnoea and pain) and side-effects from conventional chemo- and radiotherapy (hair loss, neuropathy, sore mouth and dysphagia). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.

    Time frame: 6 months from randomization

  9. Symptom burden and health related quality of life

    Measured by EORTC Questionnaire Core 30 (QLQ-C30) and the lung module (QLQ-LC13). The QLQ-C30 questionnaire consists of 30 questions with five functional scales (physical, role, cognitive, emotional and social), three symptom scales, a global health status / QoL scale, and six single items. The QLQ-LC13 module comprises both multi-item and single-item measures of lung cancer-associated symptoms (coughing, haemoptysis, dyspnoea and pain) and side-effects from conventional chemo- and radiotherapy (hair loss,neuropathy, sore mouth and dysphagia). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.

    Time frame: 12 months from randomization

  10. Quality of life (QOL) measured by EuroQol EQ-5D-5L

    EQ-5D-5L measures individual generic health status using 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, and each dimension has 5 levels depending on severity of symptoms (1 no problems, 5 extreme problems) and a VAS (visual analogue scale). The scores can then be converted into a single index number. The index value will be used for calculation of quality-adjusted life years (QALYs) for a health economic analysis of the intervention.

    Time frame: 3 months from randomization

  11. Quality of life (QOL) measured by EuroQol EQ-5D-5L

    EQ-5D-5L measures individual generic health status using 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, and each dimension has 5 levels depending on severity of symptoms (1 no problems, 5 extreme problems) and a VAS (visual analogue scale). The scores can then be converted into a single index number. The index value will be used for calculation of quality-adjusted life years (QALYs) for a health economic analysis of the intervention.

    Time frame: 6 months from randomization

  12. Quality of life (QOL) measured by EuroQol EQ-5D-5L

    EQ-5D-5L measures individual generic health status using 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, and each dimension has 5 levels depending on severity of symptoms (1 no problems, 5 extreme problems) and a VAS (visual analogue scale). The scores can then be converted into a single index number. The index value will be used for calculation of quality-adjusted life years (QALYs) for a health economic analysis of the intervention.

    Time frame: 12 months from randomization

  13. Health behavior

    Measured by single-items questions related to physical activity, alcohol consumption and smoking behavior

    Time frame: 3 months from randomization

  14. Health behavior

    Measured by single-items questions related to physical activity, alcohol consumption and smoking behavior.

    Time frame: 6 months from randomization

  15. Health behavior

    Measured by single-items questions related to physical activity, alcohol consumption and smoking behavior.

    Time frame: 12 months from randomization

  16. Self-efficacy and self-activation

    Measured by single items from Patient Activation Measure (PAM) and Health Education Impact Questionnaire (HEIQ)

    Time frame: 3 months from randomization

  17. Self-efficacy and self-activation

    Measured by single items from Patient Activation Measure (PAM) and Health Education Impact Questionnaire (HEIQ)

    Time frame: 6 months from randomization

  18. Self-efficacy and self-activation

    Measured by single items from Patient Activation Measure (PAM) and Health Education Impact Questionnaire (HEIQ)

    Time frame: 12 months from randomization

  19. Rehabilitation services

    Measured by single item question

    Time frame: 3 months from randomization

  20. Rehabilitation services

    Measured by single item question

    Time frame: 6 months from randomization

  21. Rehabilitation services

    Measured by single item question

    Time frame: 12 months from randomization

  22. Process evaluation

    Evaluation by participant-observations during training and patient sessions with subsequent qualitative semi-structured interviews with participants about their experience of the intervention components; however, only among participants who provide informed consent for this. Focus group interviews with nurse navigators and physiotherapists will be conducted about their perceptions of the intervention (facilitators and barriers). Additionally, evaluation of intervention components will be measured using quantitative single-items questions

    Time frame: 3 months from evaluation

  23. Process evaluation

    Evaluation by participant-observations during training and patient sessions with subsequent qualitative semi-structured interviews with participants about their experience of the intervention components; however, only among participants who provide informed consent for this. Focus group interviews with nurse navigators and physiotherapists will be conducted about their perceptions of the intervention (facilitators and barriers). Additionally, evaluation of intervention components will be measured using quantitative single-items questions.

    Time frame: 12 months from evaluation

  24. Cost-effectiveness

    Evaluation by health care costs and QALYs (Quality Adjusted Life Years) between the two groups.

    Time frame: 12 months from randomization

07

Study locations

6 of 6 sites recruiting
08

References and documents

Publications

  • Langballe R, Svendsen L, Jakobsen E, Dalton SO, Karlsen RV, Iachina M, Freund KM, Leclair A, Jorgensen LB, Skou ST, Ehlers JH, Torenholt R, Svendsen MN, Envold Bidstrup P. Nurse navigation, symptom monitoring and exercise in vulnerable patients with lung cancer: feasibility of the NAVIGATE intervention. Sci Rep. 2023 Dec 20;13(1):22744. doi: 10.1038/s41598-023-50161-w. PubMed 38123657 ↗
  • Langballe R, Dalton SO, Jakobsen E, Karlsen RV, Iachina M, Freund KM, Leclair A, Nielsen AS, Andersen EAW, Rosthoj S, Jorgensen LB, Skou ST, Bidstrup PE. NAVIGATE: improving survival in vulnerable patients with lung cancer through nurse navigation, symptom monitoring and exercise - study protocol for a multicentre randomised controlled trial. BMJ Open. 2022 Oct 31;12(10):e060242. doi: 10.1136/bmjopen-2021-060242. PubMed 36316074 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Dec 2026, 57 months after the start.

Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 57 months is above that.

Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2021
First posted
Sep 23, 2021
StartActual
Mar 1, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Dec 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05053997
Collaborators
Danish Cancer Society, Odense University Hospital, Vejle Hospital, Hospital of Southern Jutland
Responsible party
Susanne Dalton (Professor, MD, PhD, Zealand University Hospital) — Principal investigator
First posted
Sep 23, 2021
Start date
Mar 1, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Dec 29, 2025

Study contacts

Rikke Langballe, PhD
Contact
ril@cancer.dk
+45 35 25 79 72
Randi V Karlsen, MEd
Contact
randi@cancer.dk
+45 35 25 76 65
Susanne O Dalton, Professor
principal investigator · Zealand University Hospital
Pernille E Bidstrup, PhD
principal investigator · Danish Cancer Society
Erik Jakobsen, PhD
principal investigator · The Danish Lung Cancer Research Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion